Cardiovascular toxicity profiles of vascular-disrupting agents

Oncologist

Volumn 16, Issue 8, 2011, Pages 1120-1130

  Subbiah, Ishwaria M ^a   Lenihan, Daniel J ^b   Tsimberidou, Apostolia M ^c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cardiovascular toxicity; Combretastatin; Hypertension; Phase 1; Vascular disrupting agent

Indexed keywords

ACETYLSALICYLIC ACID; ANG 453; BEVACIZUMAB; BNC 105P; BPR 0L075; CALCIUM CHANNEL BLOCKING AGENT; CARBOPLATIN; CASPASE 3; CISPLATIN; CKD 516; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; CROLIBULIN; DENIBULIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; ICT 2588; N ACETYLCOLCHINOL PHOSPHATE; OMBRABULIN; PACLITAXEL; PLACEBO; PLINABULIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VADIMEZAN; VASCULAR TARGETING AGENT; VB 111; VERUBULIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANGIOPLASTY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; ATAXIA; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRAIN HEMORRHAGE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CATHETERIZATION; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; ENZYME ACTIVITY; FIBROSARCOMA; GLIOBLASTOMA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART REPOLARIZATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; OVARY CARCINOMA; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; QT PROLONGATION; SARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SUPRAVENTRICULAR TACHYCARDIA; SURVIVAL RATE; SYSTEMATIC REVIEW; TACHYCARDIA; THORAX PAIN; THROMBOEMBOLISM; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT; VASOSPASM;

ANGIOGENESIS INHIBITORS; BIBENZYLS; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; QUINAZOLINES; SERINE; XANTHONES;

EID: 80052188022     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0432     Document Type: Article

References (65)

1. Hinnen P, Eskens FA. Vascular disrupting agents in clinical development. Br J Cancer 2007;96:1159-1165.
2. Rustin GJ, Galbraith SM, Anderson H et al. Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-2822.
3. Delmonte A, Sessa C. AVE8062:Anew combretastatin derivative vascular disrupting agent. Expert Opin Investig Drugs 2009;18:1541-1548.
4. Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of precancerous lesions and invasive carcinomas of the colon. Br J Cancer 2001; 84:1354-1362.
5. Pilat MJ, Lorusso PM. Vascular disrupting agents. J Cell Biochem 2006; 99:1021-1039.
6. Cai SX. Small molecule vascular disrupting agents: Potential new drugs for cancer treatment. Recent Pat Anticancer Drug Discov 2007;2:79-101.
7. Baguley BC, Zhuang L, Kestell P. Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: Relation to vascular effects. Oncol Res 1997;9:55-60.
8. Siemann DW, Bibby MC, Dark GG et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11:416-420.
9. Galbraith SM, Chaplin DJ, Lee F et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 2001;21:93-102.
10. Tozer GM, Prise VE, Wilson J et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability. Cancer Res 2001; 61:6413-6422.
11. Folkes LK, Christlieb M, Madej E et al. Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals. Chem Res Toxicol 2007;20:1885-1894.
12. Gridelli C, Rossi A, Maione P et al. Vascular disrupting agents: A novel mechanism of action in the battle against non-small cell lung cancer. The Oncologist 2009;14:612-620.
13. Wang LC, Thomsen L, Sutherland R et al. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404). Neoplasia 2009;11:793-803.
14. Philpott M, Baguley BC, Ching LM. Induction of tumour necrosis factoralpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1995;36:143-148.
15. Wang LC, Woon ST, Baguley BC et al. Inhibition of DMXAA-induced tumor necrosis factor production in murine splenocyte cultures by NF-kappaB inhibitors. Oncol Res 2006;16:1-14.
16. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-148.
17. Huang A, Chen Y, Li X et al. Molecular mechanistic study of ASA404 (vadimezan)-induced endothelial cell death. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, April 17-21, 2010.
18. Pleiman CM, Baichwal V, Bhoite L et al. Vascular Disruption Effects of MPC-6827. Proceedings of the 98th Annual Meeting of the American Association for Cancer Research. Los Angeles, CA, April 14-18, 2007.
19. Evans DB, Cozens R. Evaluation of addition of the tumor-vascular disrupting agent ASA404 (vadimezan) to paclitaxel and carboplatin and the influence of subsequent ASA404 maintenance therapy using a human NSCLC xenograft model [abstract 3859]. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, April 17-21, 2010.
20. Baguley BC, Zhan X, Finlay GJ et al. The antitumor action of ASA404 (vadimezan; DMXAA); potential involvement of vascular endothelial growth factor (VEGF) [abstract]. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research, Washington, DC, April 17-21, 2010.
21. Atkinson JM, Falconer RA, Edwards DR et al. Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases. Cancer Res 2010;70:6902-6912.
22. Madlambayan GJ, Meacham AM, Hosaka K et al. Leukemia regression by vascular disruption and antiangiogenic therapy. Blood 2010;116:1539-1547.
23. Siemann DW, Shi W. Dual targeting of tumor vasculature: Combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008;28:2027-2031.
24. Wachsberger PR, Burd R, Marero N et al. Effect of the tumor vasculardamaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 2005;11:835-842.
25. Dowlati A, Robertson K, Cooney M et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-3416.
26. Stevenson JP, Rosen M, Sun W et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-4438.
27. Rustin GJ, Shreeves G, Nathan PD et al. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 2010;102:1355-1360.
28. Bilenker JH, Flaherty KT, Rosen M et al. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 2005;11:1527-1533.
29. Davis PD, Dougherty GJ, Blakey DC et al. ZD6126: A novel vasculartargeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002;62:7247-7253.
30. LoRusso PM, Gadgeel SM, Wozniak A et al. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 2008;26:159-167.
31. Tresca P, Tosi D, van Doorn L et al. Phase I and pharmacologic study of the vascular disrupting agent ombrabulin (Ob) combined with docetaxel (D) in patients (pts) with advanced solid tumors. J Clin Oncol 2010;28(15 suppl): 3023.
32. Tsimberidou AM, Akerley W, Ng C et al. Azixa, a microtubule destabilizing agent, in solid tumors: Results of a phase 1 trial. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, Denver, CO, April 21, 2009.
33. Hwu W, Akerley WL, Stephenson J et al. Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma. J Clin Oncol 2010;28(15 suppl):8531.
34. Rustin GJ, Bradley C, Galbraith S et al. 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: Phase I clinical and pharmacokinetic study. Br J Cancer 2003;88:1160-1167.
35. Jameson MB, Thompson PI, Baguley BC et al. Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 2003;88:1844-1850.
36. Garon EB, Kabbinavar FF, Neidhart JA et al. Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): The FALCON trial. J Clin Oncol 2010;28(15 suppl):7587.
37. Cooney MM, Savvides P, Agarwala S et al. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC). J Clin Oncol, ASCO Annual Meeting Proceedings Part I [abstract 5580]. Atlanta, Georgia, June 2-6, 2006.
38. McKeage MJ, Reck M, Jameson MB et al. Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 2009;65:192-197.
39. Pili R, Rosenthal MA, Mainwaring PN et al. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 2010;16:2906-2914.
40. Novartis Oncology. ATTRACT-1 Overview. Available at http://www.attractstudy.com/attract-1-researching-ASA404-in-cancer-treatment.jsp, accessed September 21, 2010.
41. Tozer GM, Prise VE, Wilson J et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 1999;59:1626-1634.
42. Bello CL, Mulay M, Huang X et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: Pharmacokinetic-pharmacodynamic evaluation of sunitinib. Clin Cancer Res 2009;15: 7045-7052.
43. Deremer DL, Ustun C, Natarajan K. Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008;30:1956-1975.
44. Johnson FM, Agrawal S, Burris H et al. Phase 1 pharmacokinetic and druginteraction study of dasatinib in patients with advanced solid tumors. Cancer 2010;116:1582-1591.
45. Chong G, Desai J, Bibby DC et al. A first-in-human, phase I pharmacodynamic (PD) and pharmacokinetic (PK) study of BNC105P, a novel vascular disrupting agent (VDA) and inhibitor of cancer cell proliferation. J Clin Oncol 2010;28(15 suppl):3054.
46. Desai J, Wong S, Chong G et al. Phase I, pharmacokinetic, and pharmacodynamic evaluation of BNC105P, a novel anticancer agent that is both a vascular disrupting agent (VDA) and an inhibitor of cancer cell proliferation. J Clin Oncol 2009;27(15 suppl):e14512.
47. Kremmidiotis G, Leske AF, Lavranos TC et al. BNC105: A novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Mol Cancer Ther 2010;9:1562-1573.
48. Chen CP, Hu CB, Yeh KC et al. Antiangiogenic activities and cisplatincombined antitumor activities of BPR0L075. Anticancer Res 2010;30: 2813-2822.
49. Kuo CC, Hsieh HP, Pan WY et al. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 2004;64:4621-4628.
50. Breitbart E, Greenberger S, Varda-Bloom N et al. A novel anti-angiogenic vector with vascular disrupting activity as a promising treatment for metastatic cancer [abstract 1369]. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research. Washington, DC, April 17-21, 2010.
51. Triozzi P, Brenner A, Giles FJ et al. A phase I trial of VB-111, a tissue and condition specific vascular disruptive anti-angiogenic agent, based on novel Vascular Targeting System™, VTS™, for treatment of patients with advanced metastatic cancer [abstract 1361]. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research. Washington, DC, April 17-21, 2010.
52. Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: Clinical and prognostic implications of troponin I evaluation. J Clin Oncol 2010;28:3910-3916.
53. Maitland ML, Bakris GL, Black HR et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 2010; 102:596-604.
54. Sarkiss MG, Yusuf SW, Warneke CL et al. Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes. Cancer 2007;109:621-627.
55. Thaker PH, Lutgendorf SK, Sood AK. The neuroendocrine impact of chronic stress on cancer. Cell Cycle 2007;6:430-433.
56. Lee JW, Shahzad MM, Lin YG et al. Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res 2009;15:2695-2702.
57. Zweifel M, Patterson ZM, Padhani AR et al. Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OXi4503 in patients with advanced solid tumors. J Clin Oncol 2010;28(15 suppl):2594.
58. Anthony SP, Read W, Rosen PJ et al. Initial results of a first-in-man phase I study of EPC2407, a novel small molecule microtubule inhibitor anticancer agent with tumor vascular endothelial disrupting activity. J Clin Oncol 2008;26(15 suppl):2531.
59. Traynor AM, Gordon MS, Alberti D et al. A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors. Invest New Drugs 2010;28:509-515.
60. Ricart AD, Cooney M, Sarantopoulos J et al. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors. J Clin Oncol 2006;24(18 suppl):3096.
61. Mita AC, Yee LK, Papadopoulos KP. Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas. J Clin Oncol 2008;26(15 suppl):3525.
62. Millward M, Mita A, Spear MA et al. Phase I trial of NPI-2358 (a novel vascular disrupting agent) plus docetaxel. J Clin Oncol 2009;27(15 suppl): 3571.
63. Ng QS, Carnell D, Milner J et al. Phase Ib trial of combretastatin A4 phosphate (CA4P) in combination with radiotherapy (RT): Initial clinical results. J Clin Oncol 2005;23(16 suppl):3117.
64. Nathan PD, Judson I, Padhani A et al. A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors. J Clin Oncol 2008;26(15 suppl):3550.
65. Hida T, Takeda K, Daga H et al. A safety and tolerability study of vadimezan in combination with docetaxel in Japanese patients with advanced or recurrent solid tumors. J Clin Oncol 2010;28(15 suppl):e13106.